PLOD1 and ovarian carcinoma: (Tan et al., 2017) reported that EP showed antitumor effects toward ovarian cancer cells through both β-catenin and STAT3 signaling pathways, and we speculate whether LH-1, which is similar to EP’s structure, also acts through this pathway.